130 related articles for article (PubMed ID: 29535127)
1.
Murcia O; Jover R; Egoavil C; Perez-Carbonell L; Juárez M; Hernández-Illán E; Rojas E; Alenda C; Balaguer F; Andreu M; Llor X; Castells A; Boland CR; Goel A
Clin Cancer Res; 2018 Jun; 24(12):2820-2827. PubMed ID: 29535127
[No Abstract] [Full Text] [Related]
2. TFAP2E-DKK4 and chemoresistance in colorectal cancer.
Ebert MP; Tänzer M; Balluff B; Burgermeister E; Kretzschmar AK; Hughes DJ; Tetzner R; Lofton-Day C; Rosenberg R; Reinacher-Schick AC; Schulmann K; Tannapfel A; Hofheinz R; Röcken C; Keller G; Langer R; Specht K; Porschen R; Stöhlmacher-Williams J; Schuster T; Ströbel P; Schmid RM
N Engl J Med; 2012 Jan; 366(1):44-53. PubMed ID: 22216841
[TBL] [Abstract][Full Text] [Related]
3. TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer.
Park SJ; Kim SM; Hong YS; Lee JL; Kim JE; Kim KP; Hong SM; Jin DH; Kim CW; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC; Kim TW
Oncology; 2015; 88(2):122-32. PubMed ID: 25341849
[TBL] [Abstract][Full Text] [Related]
4. WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
Bosch LJ; Luo Y; Lao VV; Snaebjornsson P; Trooskens G; Vlassenbroeck I; Mongera S; Tang W; Welcsh P; Herman JG; Koopman M; Nagtegaal ID; Punt CJ; van Criekinge W; Meijer GA; Monnat RJ; Carvalho B; Grady WM
Clin Cancer Res; 2016 Sep; 22(18):4612-22. PubMed ID: 27121793
[TBL] [Abstract][Full Text] [Related]
5. Transcription Factor AP2ε: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer.
Sun J; Du N; Li J; Zhou J; Tao G; Sun S; He J
Technol Cancer Res Treat; 2016 Apr; 15(2):285-95. PubMed ID: 25810491
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
[TBL] [Abstract][Full Text] [Related]
7. TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer.
Zhang ZM; Wang Y; Huang R; Liu YP; Li X; Hu FL; Zhu L; Wang F; Cui BB; Dong XS; Zhao YS
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2119-27. PubMed ID: 24996990
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
Moutinho C; Martinez-Cardús A; Santos C; Navarro-Pérez V; Martínez-Balibrea E; Musulen E; Carmona FJ; Sartore-Bianchi A; Cassingena A; Siena S; Elez E; Tabernero J; Salazar R; Abad A; Esteller M
J Natl Cancer Inst; 2014 Jan; 106(1):djt322. PubMed ID: 24273214
[TBL] [Abstract][Full Text] [Related]
9. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
[TBL] [Abstract][Full Text] [Related]
10. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
[TBL] [Abstract][Full Text] [Related]
11. TFAP2E methylation promotes 5‑fluorouracil resistance via exosomal miR‑106a‑5p and miR‑421 in gastric cancer MGC‑803 cells.
Jingyue S; Xiao W; Juanmin Z; Wei L; Daoming L; Hong X
Mol Med Rep; 2019 Jul; 20(1):323-331. PubMed ID: 31115533
[TBL] [Abstract][Full Text] [Related]
12. Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma.
Kunicka T; Prochazka P; Krus I; Bendova P; Protivova M; Susova S; Hlavac V; Liska V; Novak P; Schneiderova M; Pitule P; Bruha J; Vycital O; Vodicka P; Soucek P
BMC Cancer; 2016 Oct; 16(1):795. PubMed ID: 27733154
[TBL] [Abstract][Full Text] [Related]
13. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
15. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
18. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
20. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
